NCT05964647View on ClinicalTrials.gov

Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Healthy
Interventions
DRUG

LSD (150 µg) + ketanserin (40 mg)

"Drug: LSD (150 µg) per os, single dose~Other: Ketanserin (40 mg) per os, single dose"

DRUG

LSD (150 µg) + olanzapine (10 mg)

"Drug: LSD (150 µg) per os, single dose~Other: Olanzapine (10 mg) per os, single dose"

DRUG

LSD (150 µg) + lorazepam (2 mg)

"Drug: LSD (150 µg) per os, single dose~Other: Lorazepam (2 mg) per os, single dose"

DRUG

LSD (150 µg) + placebo

"Drug: LSD (150 µg) per os, single dose~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

DRUG

Placebo + placebo

"Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)~Other: Placebo (Capsules containing mannitol looking identical to the other drugs)"

Trial Locations (1)

4055

RECRUITING

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER